Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency. METHODS: We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease. RESULTS: Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar. CONCLUSIONS: Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our trial confirms that the kidneyprotective effects of SGLT2 inhibitors extend to the broader population of persons with chronic kidney disease without type 2 diabetes, for whom ACE inhibitors are the only pharmacologic treatments that have been shown to prevent kidney failure.3,4”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [4]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Coresh, J., Astor, B. C., McQuillan, G., Kusek, J., Greene, T., Van Lente, F., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32765 · Cited by 717
A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE
Mitch, W. E., Walser, M., Buffington, G. A., & Lemann, J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91974-7 · Cited by 459
Ruggenenti, P., Nefrologia”(GISEN), O. B. O. T. “. I. D. S. E. I., Perna, A., Mosconi, L., Pisoni, R., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00874.x · Cited by 434
Research works printed but not linked: 4
- 2001, Chin J Nephrol, 17, 77
- Hou FF, 2005, Zhonghua Yi Xue Za Zhi, 85, 458
- Zhang GH, 2005, Zhonghua Nei Ke Za Zhi, 44, 592
- Levey AS, 2000, J Am Soc Nephrol, 11, 155A
Cited by
Items 101–200 of 702
Sharma, P., Blackburn, R. C., Parke, C. L., McCullough, K., Marks, A., & Black, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007751.pub2 · Cited by 83
Jiang, C., Covell, D. J., Stepan, A. F., Plummer, M. S., & White, M. C. (2012) · Organic Letters · doi:10.1021/ol300063t · Cited by 79
Antifibrotic Effect of Tamoxifen in a Model of Progressive Renal Disease
Dellê, H., da Rocha, J. R. C., Cavaglieri, R. C., Vieira, J. M., Malheiros, D. M. A. C., & Noronha, I. L. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011010046 · Cited by 85
Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy
Weldegiorgis, M. T., de Zeeuw, D., Li, L., Parving, H., Hou, F. F., Remuzzi, G., Greene, T., & Heerspink, H. J. L. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.08.010 · Cited by 80
Self-citationCao, W., Xu, J., Zhou, Z. M., Wang, G. B., Hou, F. F., & Nie, J. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4603 · Cited by 87
“Accordingly, blockade of RAS with drugs that inhibit angiotensin-converting enzyme (ACE) or angiotensin II (Ang II) type 1 receptor (AT1) has been used as the first-line therapy for the progression of CKD (3, 16, 17, 46).”
MethodSelf-citationRenin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease
Ahmed, A., Fonarow, G. C., Zhang, Y., Sanders, P. W., Allman, R. M., Arnett, D. K., Feller, M. A., Love, T. E., Aban, I. B., Levesque, R., et al. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.013 · Cited by 78
“Potassium-sparing diuretics 87 (14) 21 Digoxin 275 (44) 62 Calcium channel blockers 126 (20) 16 Potassium supplements 240 (39) 47 Nitrates and hydralazine 95 (15) Antiarrhythmic drugs 130 (21) 18 Anticoagulants 150 (24) 30 Antiplatelet drugs 64 (10) 12 Aspirin 223 (36) 48 Insulin 94 (15) 15 Statins 86 (14) 18 Antidepr…”
InfluentialRevisiting RAAS blockade in CKD with newer potassium-binding drugs
Georgianos, P. I., & Agarwal, R. (2017) · Kidney International · doi:10.1016/j.kint.2017.08.038 · Cited by 79
Yildirim, T., Arici, M., Piskinpasa, S., Aybal-Kutlugun, A., Yilmaz, R., Altun, B., Erdem, Y., & Turgan, C. (2012) · Renal Failure · doi:10.3109/0886022x.2012.717478 · Cited by 74
“Previously, it has been shown that patients treated by nephrologists were more likely to be started RAAS blockers.(22) This study has showed that nearly one-third of CKD patients were not prescribed RAAS blockers.”
BackgroundSarafidis, P. A., & Ruilope, L. M. (2013) · Kidney International · doi:10.1038/ki.2013.355 · Cited by 80
Abdel-Kader, K. F. M., Fischer, G. S., Li, J., Moore, C. G., Hess, R., & Unruh, M. L. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.08.028 · Cited by 84
Tan, X., He, W., & Liu, Y. (2009) · Kidney International · doi:10.1038/ki.2009.346 · Cited by 86
“As a result, targeting angiotensin II alone may at best only slow, but not block or reverse, the progression of kidney functional impairment.(5,6) In this context, a combination therapy with different classes of agents that target independent pathogenic pathways may be a rational strategy for designing future therapy…”
Wang, Y., He, L., Sun, W., Lu, Y., Wang, X., Zhang, P.-Q., Wei, L., Shi-li, C., Yang, N., Hongzhen, M., et al. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.12.009 · Cited by 74
Wnt/β-catenin signaling and renin–angiotensin system in chronic kidney disease
Zhou, L., & Liu, Y. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000205 · Cited by 74
“Clinical studies showed substantial renal benefits in patients without diabetes who have advanced renal insufficiency after ACEI treatment [12].”
BackgroundAssogba, G. F. A., Couchoud, C., Roudier, C., Pornet, C., Fosse‐Edorh, S., Romon, I., Druet, C., Stengel, B., & Fagot‐Campagna, A. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.004 · Cited by 73
Scrutinio, D., & Giannuzzi, P. (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3282fd5c6f · Cited by 92
Management of hypertension in chronic kidney disease
Townsend, R. R., & Taler, S. J. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.114 · Cited by 79
Wang, S., Guillot, R., Carpentier, J., Sarazin, Y., Bour, C., Gandon, V., & Lebœuf, D. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201911761 · Cited by 70
Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease
Yamout, H., Lazich, I., & Bakris, G. L. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.005 · Cited by 74
Tomson, C., Cheung, A. K., Mann, J. F. E., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Knoll, G. A., Muntner, P., Pecoits‐Filho, R., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0834 · Cited by 78
Self-citationReporting of Estimated GFR in the Primary Care Clinic
Wyatt, C. M., Konduri, V., Eng, J., & Rohatgi, R. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.02.258 · Cited by 68
Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease
van Domburg, R. T., Hoeks, S. E., Welten, G. M. J. M., Chonchol, M., Elhendy, A., & Poldermans, D. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006101112 · Cited by 72
Chiu, Y., Chien, K., Lin, S., Chen, Y., Tsai, T., & Wu, K. (2008) · Nephron Clinical Practice · doi:10.1159/000145453 · Cited by 66
Economic burden of chronic kidney disease
Khan, S. S., & Amedia, C. A. (2008) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2007.00883.x · Cited by 67
“After 19 months 23% of patients assigned to intensified bloodpressure control and 20% allocated conventional control progressed to ESKD (HR = 1.00) Hou et al. 2006 [63] RCT of pre-ESKD patients (n = 342) assigned to benazepril or placebo and then followed for a mean of 3.4 years Benazepril therapy…”
InfluentialAcetaminophen, aspirin and progression of advanced chronic kidney disease
Evans, M., Fored, C. M., Bellocco, R., Fitzmaurice, G., Fryzek, J. P., McLaughlin, J. K., Nyren, O., & Elinder, C.-G. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn745 · Cited by 67
“Progression rates have been measured in other cohorts of patients with CKD as severe as in our study [31,32].”
ResultDeveloping Treatments for Chronic Kidney Disease in the 21st Century
Breyer, M. D., & Suszták, K. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.08.001 · Cited by 73
Wang, S., An, X., Li, S., Liu, X., Liu, Q., & Xiao, J. (2018) · Chemical Communications · doi:10.1039/c8cc08238c · Cited by 65
Ku, E., Inker, L. A., Tighiouart, H., McCulloch, C. E., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-3236 · Cited by 72
Self-citationLiu, X., Wang, J., & Dong, G. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c04575 · Cited by 63
Interdisciplinary care clinics in chronic kidney disease
Johns, T. S., Yee, J., Smith-Jules, T., Campbell, R. C., & Bauer, C. A. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0158-6 · Cited by 67
“delay the progression of CKD [40–44] and reduce”
BackgroundChen, X., Delić, D., Cao, Y., Shen, L., Shao, Q., Zhang, Z., Wu, H., Hasan, A. A., Reichetzeder, C., Gaballa, M. M. S., et al. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00528.2022 · Cited by 67
Fang, W., Oreopoulos, D. G., & Bargman, J. M. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn321 · Cited by 63
“In patients with advanced renal failure not on dialysis and patients on PD, treatment with ACE inhibitors also had substantial renal benefits [8,23].”
BackgroundRenin–angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease
Walther, C. P., Winkelmayer, W. C., Richardson, P., Virani, S. S., & Navaneethan, S. D. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa300 · Cited by 61
Ni, X., Zhang, J., Zhang, P., Wu, F., Xia, M., Ying, G., & Chen, J. (2014) · Journal of Clinical Hypertension · doi:10.1111/jch.12374 · Cited by 62
Liu, W., Chen, X., Wang, Y., Chen, Y., Chen, S., Gong, W., Chen, T., Sun, L., Zheng, C., Yin, B., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104506 · Cited by 66
Chiang, C., Sheu, M., Lin, Y., Wu, C., Yang, C., Chen, M., Hung, K., Wu, K., & Liu, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01242.x · Cited by 58
“Currently, pharmacological intervention with angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists provide only partial renoprotection in diabetes and non-diabetes CKD by reducing glomerular and tubulointerstitial damage (mesangial activation, podocyte injury, tubulointerstitial injury and i…”
BackgroundSafety of ACE inhibitor therapies in patients with chronic kidney disease
Sidorenkov, G. A., & Navis, G. J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.951328 · Cited by 61
“(2006) [93] Nephropathy Benazepril (20) n = 216 12 (5.”
The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review
Ptinopoulou, A., Pikilidou, M. I., & Lasaridis, A. N. (2012) · Hypertension Research · doi:10.1038/hr.2012.157 · Cited by 65
Epidemiology of hyperkalemia: an update
Kovesdy, C. P. (2016) · Kidney International Supplements · doi:10.1016/j.kisu.2016.01.002 · Cited by 68
Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment
Chen, H., Gong, J.-Y., Xing, K., Liu, M.-Z., Ren, H., & Luo, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.742394 · Cited by 61
“It is hydrolyzed into diacid benazeprilat through ethyl ester (80, 81).”
BackgroundGlomerular filtration rate decline as a surrogate end point in kidney disease progression trials
Badve, S. V., Palmer, S. C., Hawley, C. M., Pascoe, E. M., Strippoli, G. F., & Johnson, D. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv269 · Cited by 60
Do angiotensin II receptor blockers increase the risk of myocardial infarction?
Verdecchia, P., Angeli, F., Gattobigio, R., & Reboldi, G. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi445 · Cited by 63
Kumari, P., Liu, W., Wang, C., Dai, J., Wang, M., Yang, Q., Deng, Y., & Shao, Z. (2019) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201900430 · Cited by 55
Saruta, T., Hayashi, K., Ogihara, T., Nakao, K., Fukui, T., Fukiyama, K., & for the CASE-J Study Group (2009) · Hypertension Research · doi:10.1038/hr.2009.44 · Cited by 59
Adam, R. J., Williams, A. C., & Kriegel, A. J. (2022) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00398.2021 · Cited by 62
Bauer, T., Gitt, A. K., Jünger, C., Zahn, R., Koeth, O., Towae, F., Schwarz, A. K., Bestehorn, K. P., Senges, J., Zeymer, U., et al. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328338e5da · Cited by 60
Mishima, E., Haruna, Y., & Arima, H. (2019) · Hypertension Research · doi:10.1038/s41440-018-0116-3 · Cited by 57
Itoh, H., Ito, S., Rakugi, H., Okuda, Y., & Nishioka, S. (2019) · Hypertension Research · doi:10.1038/s41440-019-0270-2 · Cited by 57
Erler, A., Beyer, M., Petersen, J. J., Saal, K., Rath, T., Rochon, J., Haefeli, W. E., & Gerlach, F. M. (2012) · BMC Family Practice · doi:10.1186/1471-2296-13-91 · Cited by 61
“Benazepril was associated with a 52% reduction in the level of proteinuria and a 23% reduction in the rate of decline in renal function [31].”
BackgroundLin, C.-M., Yang, M., Hwang, S., & Sung, J. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2013.10.021 · Cited by 54
Zhuo, M., Li, J., Buckley, L. F., Tummalapalli, S. L., Mount, D. B., Steele, D., Lucier, D. J., & Mendu, M. L. (2022) · Kidney360 · doi:10.34067/kid.0007862021 · Cited by 55
“Hospitalization within last 30 days 585 (3) 52 (4) 0.”
BackgroundWang, R., Jin, R., Qin, Z., Bian, K., & Wang, X. (2017) · Chemical Communications · doi:10.1039/c7cc07027f · Cited by 51
Axially Chiral Dibenzazepinones by a Palladium(0)‐Catalyzed Atropo‐enantioselective C−H Arylation
Newton, C. G., Braconi, E., Kuziola, J., Wodrich, M. D., & Cramer, N. (2018) · Angewandte Chemie · doi:10.1002/ange.201806527 · Cited by 51
Tanner, L. M., Näntö‐Salonen, K., Niinikoski, H., Jahnukainen, T., Keskinen, P., Saha, H. H. T., Kananen, K., Helanterä, A., Metso, M., Linnanvuo, M., et al. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.01.043 · Cited by 51
Sánchez, J. J. G., Thompson, J. C., Scott, D. A., Evans, R., Rao, N., Sörstadius, E., James, G., NOLAN, S. T., Wittbrodt, E. T., Sultan, A. A., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02006-z · Cited by 64
“006) [113], and the REIN-1 trial of ramipril (P = 0.”
BackgroundMethodInfluentialSlowing progression of chronic kidney disease
Drawz, P. E., & Rosenberg, M. E. (2013) · Kidney International Supplements · doi:10.1038/kisup.2013.80 · Cited by 65
“Beneficial effects of ACEI have even been demonstrated in patients with advanced CKD.(11)”
Pozzi, C., Andrulli, S., Pani, A., Scaini, P., Roccatello, D., Fogazzi, G., Pecchini, P., Rustichelli, R., Finocchiaro, P., Vecchio, L. D., et al. (2012) · Journal of Nephrology · doi:10.5301/jn.5000110 · Cited by 49
Chaumont, M., Pourcelet, A., Nuffelen, M. V., Racapé, J., Leeman, M., & Hougardy, J. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12795 · Cited by 53
Wnt/β-catenin regulates blood pressure and kidney injury in rats
Xiao, L., Xu, B., Zhou, L., Tan, R. J., Zhou, D. F., Fu, H., Li, A., Hou, F. F., & Liu, Y. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.01.027 · Cited by 48
“This view is corroborated by the impressive anti-hypertensive benefits of the pharmacologic blockade of RAS using either ACE inhibitors or AT1 blockers in the clinical setting [10, 35].”
BackgroundSelf-citationChildren with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life
Zahr, R. S., Rampersaud, E., Kang, G., Weiss, M. J., Wu, G., Davis, R. L., Hankins, J. S., Estepp, J. H., & Lebensburger, J. D. (2019) · Haematologica · doi:10.3324/haematol.2018.212779 · Cited by 48
Fu, E. L., Clase, C. M., Evans, M., Lindholm, B., Rotmans, J. I., Dekker, F. W., van Diepen, M., & Carrero, J. J. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.10.006 · Cited by 55
Managing kidney disease with blood-pressure control
Wühl, E., & Schaefer, F. S. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.73 · Cited by 48
The role of renin angiotensin system inhibition in kidney repair
van der Meer, I. M., Cravedi, P., & Remuzzi, G. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-7 · Cited by 52
“, who randomly assigned 224 non-diabetic patients with an estimated GFR < 30 mL/min to benazepril or placebo [31].”
MethodTherapeutic Strategies for Heart Failure in Cardiorenal Syndromes
House, A. A., Haapio, M., Lassus, J. P. E., Bellomo, R., & Ronco, C. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.04.012 · Cited by 56
Khanal, A., Peterson, G. M., Castelino, R. L., & Jose, M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0261-1 · Cited by 57
“reduction in the level of proteinuria [36].”
Truong, P., Mandler, M. D., Zavalij, P. Y., & Doyle, M. P. (2013) · Organic Letters · doi:10.1021/ol401308d · Cited by 45
Hwang, S., Park, J., Kim, J., Jang, H. R., Kwon, G. Y., Huh, W., Kim, Y.-G., Kim, D. J., Oh, H. Y., & Lee, J. E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.009 · Cited by 47
Phosphine-Catalyzed α-Umpolung–Aldol Reaction for the Synthesis of Benzo[b]azapin-3-ones
Zhang, K., Cai, L., Hong, S., & Kwon, O. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01749 · Cited by 45
Litwin, M., Grenda, R., Śladowska, J., & Antoniewicz, J. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0223-2 · Cited by 45
“73 m(2) exerted significant antiproteinuric and renoprotective effects [20, 21].”
BackgroundChen, J., Tsai, I., Pan, H., Liao, H., Neyra, J. A., Wu, V., & Chueh, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665250 · Cited by 51
“Finally, we also identified and addressed a detailed body of published work from China, especially evidence in the Chinese language mostly emerged from the effect of RAAS inhibitors on outcomes in CKD patients (Hou et al., 2006).”
BackgroundBermúdez, R. M., García, S. G., Surribas, D. P., Castelao, A. M., & Bover, J. (2011) · PubMed · doi:10.3265/nefrologia.pre2011.jan.10807 · Cited by 69
Yu, L., Zhu, Z., Hu, X., Tang, X., & Shi, M. J. (2016) · Chemical Communications · doi:10.1039/c6cc02496c · Cited by 43
Vanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 48
“A number of studies suggested a benefit even at this stage [197,199,208], but an observational analysis pointed to an improvement of kidney function in a number of patients with advanced stage of CKD when RAAS inhibition was arrested [216], which is consistent with the abrogation of the known action of these drugs to…”
ResultAddressing the challenges of cardiorenal syndrome.
Geisberg, C. A., & Butler, J. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.5.485 · Cited by 43
Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?
Theodorakopoulou, M. P., Ortíz, A., Fernández‐Fernández, B., Kanbay, M., Minutolo, R., & Sarafidis, P. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae278 · Cited by 56
“Treatment with an angiotensin-converting enzyme inhibitor ( ACEi) or an angiotensin-receptor blocker ( ARB) remains the first choice for patients with CKD and albuminuria ( CoR I, LoE A) , based on evidence from seminal trials in people with diabetic [49 –52 ] and non-diabetic CKD [33 , 53 , 54 ].”
Baltatzi, M. S., Savopoulos, C., & Hatzitolios, A. I. (2011) · Europe PMC (PubMed Central) · Cited by 64
Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View
Fried, L. F., & Lewis, J. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10681014 · Cited by 42
“Studies, including the RENAAL, the Irbesartan Diabetes Nephropathy Trial, and the Benazapril for Advanced Renal Disease Study, used fixed doses of an ACEI or an ARB (1,2,32).”
MethodWatanabe, T., & Mishina, M. (2007) · Journal of Veterinary Medical Science · doi:10.1292/jvms.69.1015 · Cited by 41
“A recent randomized controlled clinical study demonstrated that benazepril conferred substantial renal benefits to humans with advanced renal insufficiency [14].”
BackgroundValidation of the Kidney Failure Risk Equation in Manitoba
Whitlock, R. H., Chartier, M., Komenda, P. V. J., Hingwala, J. P., Rigatto, C., Walld, R., Dart, A. B., & Tangri, N. (2017) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358117705372 · Cited by 41
“In addition, treatments such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, allopurinol, and sodium bicarbonate have been shown to slow decline in eGFR and have beneficial effects on time to kidney failure in many patients.(7-14) For these reasons, a policy to guide surveillance of vulnera…”
BackgroundFletcher, R. A., Jongs, N., Chertow, G. M., McMurray, J. J. V., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Rockenschaub, P., Rossing, P., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000248 · Cited by 40
Review article: Diabetes mellitus and heart failure — an overview of epidemiology and management
Baliga, V., & Sapsford, R. J. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109338773 · Cited by 47
Cao, H., Rao, X., Jia, J., Yan, T., & Li, D. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01989-7 · Cited by 44
“1 3 renin–angiotensin–aldosterone system (RAAS) were widely recommended for the treatment of CKD patients due to their observed benefits in alleviating the progression of CKD [3, 4].”
BackgroundManagement of traditional risk factors for the development and progression of chronic kidney disease
Lo, R. H., Narasaki, Y., Lei, S., & Rhee, C. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad101 · Cited by 45
“Studies have demonstrated their ability to reduce the risk for developing CKD progression and cardiovascular morbidities by about 50% [33].”
BackgroundGeng, H., Huang, K., Sun, T., Li, W., Zhang, X., Zhou, L., Wu, W., & Zhang, X. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo102091f · Cited by 39
Self-citationWu, L., Meng, Y., Ferguson, J. L., Wang, L., & Zeng, F. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b00012 · Cited by 39
Esnault, V. L. M., BROWN, E., Apetrei, E., Bagon, J. A., Calvo, C., deChâtel, R., Holdaas, H., Krcmery, S., & Kobalava, Z. D. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.03.006 · Cited by 39
Heerspink, H. J. L., Agarwal, R., Coyne, D. W., Parving, H. ‐., Ritz, E., Remuzzi, G., Audhya, P., Amdahl, M., Andress, D. L., & de Zeeuw, D. (2009) · American Journal of Nephrology · doi:10.1159/000225903 · Cited by 41
“These findings are corroborated by a recent post-hoc analysis demonstrating that the extent of renal protection is related more strongly to the degree of albuminuria reduction than blood pressure reduction [ ,”
ResultMcIntyre, N. J., & Taal, M. W. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328313675c · Cited by 42
Du, Y., Qing, W., Hua, L., Kan, J. J., Xi, C. J., Jin, Q. Q., & Chao, S. H. (2006) · American Journal of Nephrology · doi:10.1159/000097367 · Cited by 40
“Experimental investigations as well as clinical studies have provided strong evidence that pharmacological blockade of ACE significantly attenuates this progressive process of renal injury [”
BackgroundThe treatment of coronary artery disease in patients with chronic kidney disease
Edwards, N. C., Steeds, R. P., Ferro, C. J., & Townend, J. (2006) · QJM · doi:10.1093/qjmed/hcl101 · Cited by 40
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Neuen, B. L., Tighiouart, H., Heerspink, H. J. L., Vonesh, E. F., Chaudhari, J., Miao, S., Chan, T. M., Fervenza, F. C., Floege, J., Goicoechea, M., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070948 · Cited by 37
Self-citationChu, C., Zeng, S., Hasan, A. A., Hocher, C., Krämer, B. K., & Hocher, B. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14660 · Cited by 39
“All the RCTs were multicentre, except 1 done by Hou et al.(34) Seven of them compared ACEIs with controls, 4 compared ARBs with controls.”
MethodKuo, K., Hung, S., Liu, J., Chang, Y., Hsu, C.-C., & Tarng, D. (2015) · Scientific Reports · doi:10.1038/srep17150 · Cited by 36
Mark, P. B., Carrero, J. J., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Coresh, J., Surapaneni, A., Brunskill, N. J., Chalmers, J. P., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac825 · Cited by 40
Machine learning models to predict end-stage kidney disease in chronic kidney disease stage 4
Takkavatakarn, K., Oh, W., Cheng, E., Nadkarni, G. N., & Chan, L. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03424-7 · Cited by 43
“4 Reliability diagram of all models the most effective methods for delaying the progression of the disease in early CKD [25–27].”
MethodRole of Vitamin D and Its Analogues in Diabetic Nephropathy: A Meta-analysis
Gupta, S., Goyal, P., Feinn, R., & Mattana, J. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.12.005 · Cited by 38
Palladium‐Catalyzed Oxidative Cycloaddition through CH/NH Activation: Access to Benzazepines
Wang, L., Huang, J., Peng, S., Liu, H., Jiang, X., & Wang, J. (2012) · Angewandte Chemie · doi:10.1002/ange.201208076 · Cited by 35
Identification and Management of Albuminuria in the Primary Care Setting
Kuritzky, L., Toto, R. D., & Buren, P. N. V. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00424.x · Cited by 39
Renin-Angiotensin Inhibition in Diastolic Heart Failure and Chronic Kidney Disease
Ahmed, A., Rich, M. W., Zile, M. R., Sanders, P. W., Patel, K., Zhang, Y., Aban, I., Love, T. E., Fonarow, G. C., Aronow, W. S., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.031 · Cited by 37
Viazzi, F. C., Bonino, B., Cappadona, F., & Pontremoli, R. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1435-5 · Cited by 36
“Over the years, the knowledge of the pathophysiology of their numerous mechanisms of action has increased, and their efficacy has been repeatedly proven [7–10].”
BackgroundSarafidis, P. A., Schmieder, R. E., Burnier, M., Persu, A., Januszewicz, A., Halimi, J., Arıcı, M., Ortíz, A., Wanner, C., Mancia, G., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae041 · Cited by 35
“Following seminal clinical trials, in people with diabetic [39 – 42 ] and non-diabetic CKD [20 , 43 , 44 ] an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin-receptor blocker (ARB) is the treatment of choice, especially in those with moderately or severely increased albuminuria,…”
Metadata
- Authors
- Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., & Geng, R. W.
- Affiliations
- Nanfang Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-12
- Volume
- 354
- Issue
- 2
- Pages
- 131-140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2063210769
- Cited by
- 710
- References
- 22
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 31 · 2023: 42 · 2022: 42 · 2021: 43 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 23 · 2016: 29 · 2015: 24 · 2014: 39 · 2013: 30 · 2012: 39
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- benazepril, ACE inhibitors, end-stage renal disease, renal protection, proteinuria, renal function decline, serum creatinine doubling, non-diabetic patients, adverse events
- MeSH terms
- Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, China, Creatinine, Double-Blind Method, Female, Humans, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.